Why Palantir Stock Plummeted Last Month But Is Soaring in July

Palantir shares rebounded in July, rising about 11% after a June sell-off tied to AI-software underperformance and renewed risk around its expiring ~$440M UK NHS contract (set not to be renewed early next year). Sentiment improved as Michael Burry trimmed his Palantir short and DA Davidson upgraded the stock to Buy, raising its 12-month price target from $165 to $175 (Jul 2). The stock also got a boost from expanding its partnership with Nvidia, integrating Nemotron AI models into Palantir’s AI stack for US and allied government customers.

Analysis

This reads more like a positioning reset than a fundamental inflection. PLTR’s multiple is still hostage to whether the market wants to pay for software-duration or just near-term AI capex; that makes the stock unusually sensitive to sentiment swings in NVDA and other infrastructure names. The key second-order effect is that any renewed AI-software bid will likely compress dispersion inside the group, but the highest-beta names with the most crowded ownership can outperform on the way up and then mean-revert just as fast.

The NHS overhang matters less for the direct revenue line than for the narrative around government stickiness: if that renewal slips, investors will extrapolate a higher churn risk across public-sector deals globally, which can cap the multiple even if growth stays intact. Conversely, the Nvidia partnership is more useful as validation than economics; it improves PLTR’s credibility in government inference workloads, but it does not change the fact that the market is still waiting for durable evidence of commercial expansion at scale. NVDA is the cleaner beneficiary because any software-stack adoption still pulls through hardware demand and makes its ecosystem harder to displace.

Contrarian view: the market may be underestimating how much of PLTR’s recent volatility is driven by short-interest dynamics rather than revised cash-flow expectations. If that’s right, the stock can keep squeezing for days or weeks, but a sustained re-rating over 1-3 months likely requires either explicit contract renewal clarity or another quarter of upside on net dollar retention and remaining performance obligations. What would falsify the bullish setup is a confirmed NHS nonrenewal, slowing bookings commentary, or a rotation back into semis that drains attention from software.

On balance, this is a tradeable tape, but not a conviction long on the business model alone. The better risk/reward is relative value: own the AI toll-collector and fade the high-multiple software name if sentiment turns back toward infrastructure. If the software rally broadens, PLTR can still outperform briefly, but the margin of safety remains thin at current valuation levels.

Key Decisions for Investors

• Prefer long NVDA vs short PLTR as a 1-3 month relative-value pair: NVDA has direct monetization of AI spend, while PLTR is still more dependent on sentiment and contract headlines. Use any PLTR strength into analyst-driven spikes to add the short; thesis breaks if PLTR gets clear NHS renewal confirmation and posts accelerating commercial bookings.
• For event-driven momentum, consider a tactical long PLTR only on pullbacks, not breakouts, with a tight trading stop tied to a failure of the July rebound. The setup is a 2-6 week squeeze trade, not a long-duration compounder at these levels.
• Buy NVDA on softness as the cleaner beneficiary of any AI software-to-hardware read-through. If investors rotate back to software, NVDA should still participate through ecosystem pull-through; if they rotate back to hardware, NVDA has the more durable fundamental bid.
• Avoid initiating a fresh outright short in PLTR until the market has either priced in the NHS risk or the stock loses its recent momentum shelf. The near-term risk is a short squeeze; the better short entry is after a failed rally or on confirmed negative contract news.
• Set an alert around the NHS renewal decision window and next earnings commentary on bookings/commercial growth. If management does not quantify replacement revenue or renewal progress, the market will keep discounting that exposure into the multiple.